Evaluating the costs and benefits of using combination therapies

Anthony Rodgers, Tracey-Lea Laba and Stephen Jan
Med J Aust 2014; 201 (8): . || doi: 10.5694/mja14.00675
Published online: 20 October 2014

To the Editor: Clarke and Avery make an important point highlighting the substantial costs arising from a loophole allowing multibrand fixed-dose combinations (FDCs) listed on the Pharmaceutical Benefits Scheme (PBS) to retain price premiums long after premiums on their individual components have eroded.1

  • Anthony Rodgers
  • Tracey-Lea Laba
  • Stephen Jan

  • The George Institute for Global Health, Sydney, NSW.

Competing interests:

The George Institute for Global Health secured an exclusive global licence in December 2012 for the polypills used in recent trials, following a decision by Dr Reddy's Laboratories Ltd not to proceed with taking the products to market because of existing regulatory requirements.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.